People: Orthologic Corp. (CAPS.O)

CAPS.O on Consolidated Issue listed on NASDAQ Capital Market

0.82USD
9 Feb 2010
Price Change (% chg)

$-0.03 (-3.29%)
Prev Close
$0.85
Open
$0.84
Day's High
$0.90
Day's Low
$0.82
Volume
49,543
Avg. Vol
18,072
52-wk High
$1.04
52-wk Low
$0.35

view people for:

Summary

Name Age Since Current Position
Holliman, John 55 2006 Executive Chairman of the Board, Principal Executive Officer
Steer, Randolph 59 2006 President
Taeger, Leslie 58 2006 Chief Financial Officer, Senior Vice President
Shinbaum, Dana 46 2005 Vice President - Business Development
Feldman, Fredric 68 1991 Director
Howse, Elwood 69 1987 Director
White, Augustus 73 1993 Director
Wardell, William 70 2006 Director
» Insider Trading

Biographies

Name Description
Holliman, John John M. Holliman, III, became Executive Chairman and Principal Executive Officer of OrthoLogic Corp. on April 5, 2006 and has served as a Director of the Company since September 1987 and as Chairman of the Board of Directors since August 1997. Since February 1993 he has been a general partner of entities, which are the general partners of Valley Ventures, LP (formerly known as Arizona Growth Partners, LP), Valley Ventures II, LP, Valley Ventures III Annex, LP, all of which are venture capital funds that invest principally in life science companies.
Steer, Randolph Randolph C. Steer, MD, Ph.D. became President of OrthoLogic Corp. on April 5, 2006. Dr. Steer has been an independent pharmaceutical, biotechnology and medical devices consultant since 1989, and has provided consulting services to OrthoLogic since 2002. He has a broad scientific, medical and business background, including extensive experience in pre-clinical, clinical and regulatory affairs, having held key management positions in leading corporations and having served as an advisor to many companies in the United States and abroad. Dr. Steer has also advised numerous venture capital firms, investment banks and independent investors on the commercial development of drugs, biologics, diagnostics and medical devices. He has served as Associate Director of Medical Affairs at Marion Laboratories; Medical Director at Ciba Consumer Pharmaceuticals (Ciba-Geigy Corporation); Vice President, Senior Vice President and Member of the Executive Committee at Physicians World Communications Group; Chairman, President and Chief Executive Officer of Advanced Therapeutics Communications International, a global drug regulatory group, and Chairman and Chief Executive Officer of Vicus.com, Inc. He is a member of the Board of Directors of Techne Corporation and BioCryst Pharmaceuticals. Dr. Steer received his MD degree from the Mayo Medical School and his Ph.D. from the University of Minnesota, where he also completed a residency and subspecialty fellowship in clinical and chemical pathology. He is a Fellow of the American College of Clinical Pharmacology.
Taeger, Leslie Les M. Taeger Senior Vice President and Chief Financial Officer on January 16, 2006. Mr. Taeger most recently served as Chief Financial Officer of CardioTech International, Inc. (“CardioTech”). CardioTech is a publicly-traded, medical device company that develops, manufactures and sells advanced products for the treatment of cardiovascular disease. From September, 2000 to February, 2004, when Mr. Taeger became Chief Financial Officer of CardioTech, Mr. Taeger served as Chief Financial Officer of Gish Biomedical, Inc. (“Gish”). Gish, which became a subsidiary of CardioTech pursuant to a merger transaction involving the companies in April, 2003, specializes in the manufacture and sale of products used in open-heart surgery, vascular access and orthopedic surgery. Prior to his employment with CardioTech and Gish, Mr. Taeger was employed for over five years as Chief Financial Officer of Cartwright Electronics, Inc., a division of Meggitt, PLC. Mr. Taeger is a Certified Public Accountant, with a Bachelor degree in accounting.
Shinbaum, Dana Dana B. Shinbaum is Vice President of Business Development of OrthoLogic Corp. in October 2005. Previously he served as Vice President, Product Planning and Market Analytics at Savient Pharmaceuticals, Inc., and has over eighteen years of experience in the pharmaceutical/biotechnology industry. While at Savient his responsibilities included creating and developing new business opportunities, leading global project teams and managing product launches. He played key strategic planning roles in Savient’s acquisition of Rosemont Pharmaceuticals Ltd. and the divestiture of Bio-Technology General Ltd., Savient’s global biologics business. Prior to joining Savient, Mr. Shinbaum was at Wyeth-Ayerst Laboratories, where he held market planning and marketing roles of increasing responsibility, including Product Manager for the PREMARIN® franchise. Mr. Shinbaum received a Master of Business Administration, summa cum laude, from Drexel University in Philadelphia and a Bachelor of Arts degree from Lafayette College in Easton, Pennsylvania.
Feldman, Fredric Fredric J. Feldman, Ph.D. is Director of OrthoLogic Corp. since 1991. He has been the President of FJF Associates, a consultant to health care venture capital and emerging companies, since February 1992. From September 1995 to June 1996, he was the Chief Executive Officer of Biex, Inc., a women’s healthcare company. He served as Chief Executive Officer of Oncogenetics, Inc., a cancer genetics reference laboratory from 1992 to 1995. Between 1988 and 1992, Dr. Feldman was the President and Chief Executive Officer of Microgenics Corporation, a medical diagnostics company. He has been a director of a number of public and private companies involved in the healthcare industry.
Howse, Elwood Elwood D. Howse, Jr., has served as a Director of OrthoLogic Corp. since September 1987. In 1982, Mr. Howse founded Cable, Howse and Ragen, investment banking and stock brokerage firm, now owned by Wells Fargo and known as Ragen MacKenzie. In 1977, Mr. Howse co-founded Cable & Howse Ventures, an early stage venture capital firm focused on technology. In 1976, he served as Vice President, Corporate Finance, for Foster & Marshall, a northwest stock brokerage firm. In 1974 he was the Chief Financial Officer of Seattle Stevedore Company and the Miller Produce Company. Mr. Howse has served as a corporate director and advisor to various public, private and non-profit enterprises. He served on the board of the National Venture Capital Association and is past President of the Stanford Business School Alumni Association. He currently serves on the boards of directors of BSQUARE Corporation (BSQR), Formotus, Inc., Perlego Systems Inc., The PowerTech Group, Inc., and not-for-profits, Junior Achievement Worldwide, Junior Achievement of Washington and the MadreMonte Foundation.
White, Augustus Augustus A. White became a Director of OrthoLogic Corp. in July 1993. He is the former Master of the Oliver Wendell Holmes Society and currently the Ellen and Melvin Gordon Distinguished Professor of Medical Education and Professor of Orthopedic Surgery at the Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology (1978 – 2007). He is the Orthopedic Surgeon-in-Chief, Emeritus, at the Beth Israel Deaconess Medical Center in Boston since 1990. From 1992 to 1994, he served as the Chief of Spine Surgery at Beth Israel and is a former Director of the Daniel E. Hogan Spine Fellowship Program. He is a graduate of Brown University, the Stanford University Medical School, holds a Ph.D. from the Karolinska Institute in Stockholm, and graduated from the Advanced Management Program at the Harvard Business School. Dr. White is a recipient of the Bronze Star, which he earned while stationed as a Captain in the U.S. Army Medical Corps in Vietnam. Dr. White is currently a director of Zimmer Holdings, Inc., a publicly held designer, marketer and manufacturer of orthopedic products.
Wardell, William William M. Wardell is Director of OrthoLogic Corp. Dr. Wardell was appointed by the OrthoLogic Board of Directors on February 11, 2006, to fill a vacancy (Class III) on the Board. He owns and operates the consulting firm Wardell Associates International LLC in Princeton, NJ, where he specializes in drug development, regulatory approval, and safety for a range of pharmaceutical and biotechnology companies. Dr. Wardell has published over one hundred scientific papers and four books, and has testified as an expert in drug development during several Congressional hearings. Dr. Wardell has 22 years of experience in the healthcare industry, holding leadership positions as President, Protein Engineering Corporation (now DYAX); Senior Vice President of Drug Development, Parke-Davis; Vice President and Medical Director, Boehringer Ingelheim Pharmaceuticals; Senior Scientific Officer, Covance; and Executive Director of the Covance Institute for Drug Development Sciences. During his tenure at these companies, Dr. Wardell was responsible for 11 approved New Drug Applications. He previously served as an associate professor of Pharmacology, Toxicology and Medicine, attending on the Clinical Pharmacology consultation service of Strong Memorial Hospital at the University of Rochester Medical Center, where he co-founded and directed the University’s Center for the Study of Drug Development. Dr. Wardell earned his MA, PhD in pharmacology, and MD at the University of Oxford (UK), and was a Merck International Fellow in Clinical Pharmacology and Medicine under Dr. Louis Lasagna at the University of Rochester / Strong Memorial Hospital. He currently serves on the Board of Directors of PhytoCeutica, Inc. and the Scientific Advisory Board of Eleos, Inc.

Basic Compensation

Name Fiscal Year Total
Holliman, John 292,000
Steer, Randolph 451,000
Taeger, Leslie 399,000
Shinbaum, Dana 355,000
Feldman, Fredric --
Howse, Elwood --
White, Augustus --
Wardell, William --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Holliman, John 0 0
Steer, Randolph 0 0
Taeger, Leslie 0 0
Shinbaum, Dana 50,000 81,500
Feldman, Fredric 0 0
Howse, Elwood 0 0
White, Augustus 0 0
Wardell, William 0 0

Insider Trading

Name Shares Traded Price
WARDELL WILLIAM M 7,660 $0.92
WARDELL WILLIAM M 10,000 $0.92
FELDMAN FREDERIC J 8,000 $0.89
HOWSE ELWOOD D JR 20,000 $0.81
HOLLIMAN JOHN M III 20,000 $0.74
WHITE AUGUSTUS A III 7,000 $0.75
WHITE AUGUSTUS A III 7,000 $0.75
STEER RANDOLPH C 20,000 $0.89
WARDELL WILLIAM M 7,000 $0.72
WARDELL WILLIAM M 8,000 $0.72
HOLLIMAN JOHN M III 10,000 $0.67
HOWSE ELWOOD D JR 20,000 $0.55
FELDMAN FREDERIC J 15,000 $0.53
WHITE AUGUSTUS A III 7,407 $0.55
WHITE AUGUSTUS A III 12,224 $0.55
WHITE AUGUSTUS A III 5,425 $0.51
HOLLIMAN JOHN M III 10,000 $0.48
WHITE AUGUSTUS A III 21,735 $0.46
BVF PARTNERS L P 153,000 $0.63
BVF PARTNERS L P 3,100 $0.75
BVF PARTNERS L P 221,400 $0.63
BVF PARTNERS L P 9,000 $0.75
BVF PARTNERS L P 557,000 $0.63
BVF PARTNERS L P 3,000 $0.75
BVF PARTNERS L P 1,600 $0.63
» Full list on Insider Trading
view people for: